Fractyl Health, Inc. announced the call of its outstanding Tranche A Common Stock Purchase Warrants for cancellation or exercise at a price of $1.05 per share.
The warrants were tied to the August 2025 public offering and holders have until December 30, 2025, to make their decision.
The Company aims to potentially raise up to $17.9 million in gross proceeds through this warrant exercise.
Warrant Call
Tranche A Warrants tied to the August 2025 public offering are to be called for either cancellation or exercise at $1.05 per share by December 30, 2025.
Potential Proceeds
If all warrants are exercised, Fractyl could secure an additional $17.9 million in gross proceeds before fees and expenses.
Clinical Milestones
The warrant call follows the release of positive three-month randomized midpoint data from the REMAIN-1 study.
- The warrant call indicates Fractyl's confidence in its clinical and market performance.
- The potential proceeds would bolster the company's financial position for upcoming clinical program advancements.
Fractyl Health's decision to call its Tranche A Warrants reflects strategic financial planning and signals positive clinical progress.